Advertisement

Iatrogenic Injury: Radiation and Drug Effects

  • Rodney A. Schmidt

Abstract

Virtually all therapies of modern medicine carry the potential for harm. Fortunately, the potential is usually low and the consequences are mild. Nevertheless, iatrogenic disease is common and can result in the death of patients. For example, it is estimated that the incidence of adverse drug reactions most likely lies between 10% and 20% but may range as high as 28%.1 Drug reactions cause between 2.9% and 6.2% of all hospital admissions and as many as 0.31% of all hospital deaths.1,2 A substantial fraction of drug reactions involve the respiratory system. Radiation therapy is also associated with adverse effects. Estimates of radiation pneumonitis range from 5% to 20% for patients given tumoricidal doses of thoracic radiation.3–5

Keywords

Pulmonary Edema Radiation Injury Radiation Pneumonitis Obliterative Bronchiolitis Iatrogenic Injury 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Davis DM, ed. Textbook of adverse drug reactions. 3d Ed. New York: Oxford University Press, 1985: 1–38.Google Scholar
  2. 2.
    Turner WM, Milstein JB. Drug induced diseases. In: Pharmacotherapy: A pathophysiologic approach. 1st Ed. New York: Elsevier, 1989: 60–67.Google Scholar
  3. 3.
    Gross NJ. Pulmonary effects of radiation therapy. Ann Intern Med 1977; 86: 81–92.PubMedCrossRefGoogle Scholar
  4. 4.
    White DC. Lung. In: An atlas of radiation histopathology. Technical Information Center, Office of Public Affairs, U.S. Energy Research and Development Administration, 1975: 106–125.Google Scholar
  5. 5.
    Gross NJ. The pathogenesis of radiation-induced lung damage. Lung 1981; 159: 115–125.PubMedCrossRefGoogle Scholar
  6. 6.
    Groover TA, Christie AC, Merritt EA. Observations on the use of the copper filter in the roentgen treatment of deepseated malignancies. South Med J 1922; 15: 440444.Google Scholar
  7. 7.
    Hines LE. Fibrosis of the lung following roentgen-ray treatments for tumor. JAMA 1922; 79: 720–722.CrossRefGoogle Scholar
  8. 8.
    Tyler AF, Blackman JR. Effect of heavy radiation on the pleurae and lungs. J Radiol 1922; 3: 469–475.Google Scholar
  9. 9.
    Rubin P, Casarett GW. Clinical radiation pathology. Philadelphia: WB Saunders, 1968.Google Scholar
  10. 10.
    Evans WA, Leucutia T. Intrathoracic changes induced by heavy radiation. AJR 1925; 13: 206–220.Google Scholar
  11. 11.
    Desjardins AU. The reaction of the pleura and lungs to roentgen rays. AJR 1926; 16: 444–453.Google Scholar
  12. 12.
    Fajardo LF, Berthong M. Radiation injury in surgical pathology: Part I. Am J Surg Pathol 1978; 2 (2): 159–199.PubMedCrossRefGoogle Scholar
  13. 13.
    Schuh D, Kemmer C. Radiation pneumonitis. Morphology and pathogenesis. Zentralbl Allg Pathol Pathol Anat 1988; 134 (7): 611–626.Google Scholar
  14. 14.
    Coggle JE, Lambert BE, Moores SR. Radiation effects in the lung. Environ Health Perspect 1986; 70: 261–291.PubMedCrossRefGoogle Scholar
  15. 15.
    McDonald S, Rubin P, Maasilta P. Response of normal lung to irradiation: Tolerance doses/tolerance volumes in pulmonary radiation. In: Vaeth JM, Meyer JL, eds. Radiation tolerance of normal tissue. Front Radiat Ther Oncol 1989; 23: 255–276.Google Scholar
  16. 16.
    Rosiello RA, Merrill WW. Radiation-induced lung injury. Clin Chest Med 1990; 11 (1): 65–71.PubMedGoogle Scholar
  17. 17.
    Lingos TI, Recht A, Vicini F, Abner A, Silver B, Harris JR. Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991; 21 (2): 355–360.PubMedCrossRefGoogle Scholar
  18. 18.
    Prince A, Jack WJ, Kerr GR, Rodger A. Acute radiation pneumonitis after postmastectomy irradiation: Effect of fraction size. Clin Oncol (R Coll Radiol) 1990;2(4):224229.Google Scholar
  19. 19.
    Newman G, Bell J, Goddard P, Bullimore JA. Pulmonary changes in breast cancer patients treated by three different radiotherapy techniques. Clin Oncol (R Coll Radiol) 1989; 1 (2): 91–96.CrossRefGoogle Scholar
  20. 20.
    Weshler Z, Breuer R, Or R, et al. Interstitial pneumonitis after total body irradiation: Effect of partial lung shielding. Br J Haematol 1990; 74 (1): 61–64.PubMedCrossRefGoogle Scholar
  21. 21.
    Coscina WF, Arger PH, Mintz MC, Coleman BG. CT demonstration of pulmonary effects of tangential beam radiation. J Comput Assist Tomogr 1986;10(4):600602.Google Scholar
  22. 22.
    Keane TJ, Van Dyk J, Rider WD. Idiopathic interstitial pneumonia following bone marrow transplantation: The relationship with total body irradiation. Int J Radiat Oncol Biol Phys 1981; 7: 1365–1370.PubMedCrossRefGoogle Scholar
  23. 23.
    Siemann DW, Rubin P, Penney DP. Pulmonary toxicity following multifraction radiotherapy. Br J Cancer 1986; 53 (Suppl VII): 365–367.Google Scholar
  24. 24.
    Minna JD, Pass H, Glatstein E, Ihde DC. Cancer of the lung. In: De Vita VT, Jr., Heldman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. 3d Ed. Philadelphia: JB Lippincott, 1989: 591–705.Google Scholar
  25. 25.
    Rubin P, Shapiro DL, Finklestein JN, Penney DP. The early release of surfactant following lung irradiation of alveolar type II cells. Int J Radiat Oncol Biol Phys 1980; 6: 75–77.PubMedCrossRefGoogle Scholar
  26. 26.
    Hallman M, Maasilta P, Kivisaari L, Mattson K. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am Rev Respir Dis 1990; 141: 998–1005.PubMedCrossRefGoogle Scholar
  27. 27.
    Ward WF, Molteni A, Solliday SH, Jones GR. The relationship between endothelial dysfunction and collagen accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys 1985; 11: 1985–1990.PubMedCrossRefGoogle Scholar
  28. 28.
    Gross NJ, Narine KR, Colletti-Squinto L. Replicative activity of lung type 2 cells following lung X-irradiation. Radiat Res 1987; 111: 143–150.PubMedCrossRefGoogle Scholar
  29. 29.
    Ward WF, Solliday NH, Molteni A, Port CD. Radiation injury in rat lung. II. Angiotensin-converting enzyme activity. Radiat Res 1983; 96: 284–293.PubMedCrossRefGoogle Scholar
  30. 30.
    T’sao CH, Ward WF, Port CD. Radiation injury in rat lung. III. Plasminogen activator and fibrinolytic inhibitor activities. Radiat Res 1983; 96: 294–300.CrossRefGoogle Scholar
  31. 31.
    Ward WF, Molteni A, T’sao C, Solliday NH. Pulmonary endothelial dysfunction induced by unilateral as compared to bilateral thoracic irradiation in rats. Radiat Res 1987; 111: 101–106.PubMedCrossRefGoogle Scholar
  32. 32.
    Van Dyk J, Keane IT Kan S, Rider WD, Fryer CJH. Radiation pneumonitis following large single dose irradiation: A re-evaluation based on absolute dose to the lung. Int J Radiat Oncol Biol Phys 1981; 7: 461–467.PubMedCrossRefGoogle Scholar
  33. 33.
    Stover DE. Pulmonary toxicity. In: De Vita VT, Jr., Heldman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. 3d Ed. Philadelphia: JB Lippincott, 1989: 591–705.Google Scholar
  34. 34.
    Gross NJ. The pathogenesis of radiation-induced lung damage. Lung 1981; 159: 115–125.PubMedCrossRefGoogle Scholar
  35. 35.
    Bell J, McGivern D, Bullimore J, Hill J, Davies ER, Goddard P. Diagnostic imaging of post-irradiation changes in the chest. Clin Radiol 1988; 39 (2): 109–119.PubMedCrossRefGoogle Scholar
  36. 36.
    Ikezoe J, Morimoto S, Takashima S, Takeuchi N, Arisawa J, Kozuka T. Acute radiation-induced pulmonary injury: Computed tomography evaluation. Semin Ultrasound CT MR 1990; 11 (5): 409–416.PubMedGoogle Scholar
  37. 37.
    Lichtenstein H. X-ray diagnosis of radiation injuries of the lung. Dis Chest 1960; 38: 294–297.PubMedCrossRefGoogle Scholar
  38. 38.
    Pezner RD, Horak DA, Sayegh HO, Lipsett JA. Spontaneous pneumothorax in patients irradiated for Hodgkin’s disease and other malignant lymphomas. Int J Radiat Oncol Biol Phys 1990; 18 (1): 193–198.PubMedCrossRefGoogle Scholar
  39. 39.
    Cameron SJ, Grant IWB, Lutz W, et al. The early effect of irradiation on ventilatory function in bronchial carcinoma. Clin Radio] 1969; 20: 12–18.CrossRefGoogle Scholar
  40. 40.
    Libshitz HI, Southard ME. Complications of radiation therapy: The thorax. Semin Roentgenol 1974; 9: 41–49.PubMedCrossRefGoogle Scholar
  41. 41.
    Bennett DE, Million RR, Ackerman LV. Bilateral radiation pneumonitis, a complication of the radiotherapy of bronchogenic carcinoma. Cancer (Philadelphia) 1969; 23: 1001–1018.CrossRefGoogle Scholar
  42. 42.
    Gibson PG, Bryant DH, Morgan GW, et al. Radiation-induced lung injury: A hypersensitivity pneumonitis? Ann Intern Med 1988; 109 (4): 288–291.PubMedCrossRefGoogle Scholar
  43. 43.
    Wechsler RJ, Ayyangar K, Steiner RM, Yelovich R, Moylan DM. The development of distant pulmonary infiltrates following thoracic irradiation: The role of computed tomography with dosimetric reconstruction in diagnosis. Comput Med Imaging Graph 1990; 14 (1): 43–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Sherman ML, Datta R, Hallahan DE, Weichselbaum RR, Kufe DW. Regulation of tumor necrosis factor gene expression by ionizing radiation in human myeloid leukemia cells and peripheral blood monocytes. J Clin Invest 1991; 87: 1794–1797.PubMedCrossRefGoogle Scholar
  45. 45.
    Fulkerson WJ, Mclendon RE, Prosnitz LR. Adult respiratory distress syndrome after limited thoracic radiotherapy. Cancer (Philadelphia) 1986; 57: 1941–1946.CrossRefGoogle Scholar
  46. 46.
    Byhardt RW, Abrams R, Almagro U. The association of adult respiratory distress syndrome (ARDS) with thoracic irradiation (RT). Int J Radiat Oncol Biol Phys 1988; 15: 1441–1446.PubMedCrossRefGoogle Scholar
  47. 47.
    Hendry JH. Response of human organs to single (or fractionated equivalent) doses of irradiation. Int J Radiat Biol 1989; 56 (5): 671–700.CrossRefGoogle Scholar
  48. 48.
    Hellman S. Principles of radiation therapy. In: De Vita VT, Jr., Heldman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. 3d Ed. Philadelphia: JB Lippincott, 1989: 247–275.Google Scholar
  49. 49.
    Fornace AJ, Jr., Nebert DW, Hollander MC, et al. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol Cell Biol 1989;9(10):4196 4203.Google Scholar
  50. 50.
    Weichselbaum RR, Hallahan DE, Sukhatme V, Dritschilo A, Sherman ML, Kufe DW. Biological consequences of gene regulation after ionizing radiation exposure. J Natl Cancer Inst 1991; 83 (7): 480–488.PubMedCrossRefGoogle Scholar
  51. 51.
    Eldor A, Vlodaysky I, Fuks Z, Matzner Y, Rubin DB. Arachidonic metabolism and radiation toxicity in cultures of vascular endothelial cells. Prostaglandins Leukot Essent Fatty Acids 1989; 36 (4): 251–258.PubMedCrossRefGoogle Scholar
  52. 52.
    Cooper JAD, Jr., White DA, Matthay RA. Drug-induced pulmonary disease: Part 1:Cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321–340.PubMedGoogle Scholar
  53. 53.
    Glaholm J, Repetto L, Yarnold JR, et al. Carboplatin (JM8), etoposide (VP16) and thoracic irradiation for small cell lung cancer (S.C.L.C.): An evaluation of lung toxicity. Radiother Oncol 1988; 12 (1): 31–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Roggli VL, Kolbeck J, Sanfilippo F, Shelburne JD. Pathology of human mesothelioma: Etiologic and diagnostic considerations. Pathol Annu 1987; 22 (Pt. 2): 91–132.PubMedGoogle Scholar
  55. 55.
    Samuels ML, Johnson DE, Holoye PY, Lanzotti VJ. Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA 1976; 235: 1117–1120.PubMedCrossRefGoogle Scholar
  56. 56.
    Warren S, Spencer J. Radiation reaction in the lung. AJR 1940; 43: 682–701.Google Scholar
  57. 57.
    Pezner RD, Bertrand M, Cecchi GR, Paladugu RR, Kendregan BA. Steroid-withdrawal radiation pneumonitis in cancer patients. Chest 1984; 85 (6): 816–817.PubMedCrossRefGoogle Scholar
  58. 58.
    Castellino RA, Glatstein E, Turbow MM, et al. Latent radiation injury of lungs or heart activated by steroid withdrawal. Ann Intern Med 1974; 80: 593–599.PubMedCrossRefGoogle Scholar
  59. 59.
    Fryer CJH, Fitzpatrick PJ, Rider WD, Poon P. Radiation pneumonitis: Experience following a large single dose of radiation. IntJ Radiat Oncol Biol Phys 1978; 4: 931–936.CrossRefGoogle Scholar
  60. 60.
    Smith PG, Doll R. Mortality from cancer and all causes among British radiologists. Br J Radiol 1981; 54: 187194.Google Scholar
  61. 61.
    Sources and effects of ionizing radiation. United Nations Scientific Committee on the Effects of Atomic Radiation 1977 Report to the General Assembly, with annexes. United Nations, New York, 1977. [Official Records of the General Assembly, 32d Session, Suppl. No. 40 (A/32/40).]Google Scholar
  62. 62.
    Boice JD, Jr. Carcinogenesis-a synopsis of human experience with external exposure in medicine. Health Phys 1988; 55 (4): 621–630.PubMedCrossRefGoogle Scholar
  63. 63.
    Davis FG, Boice JD, Kelsey JL, Monson RR. Cancer mortality after multiple fluoroscopic examinations of the chest. J Natl Cancer Inst 1987; 78 (4): 645–652.PubMedGoogle Scholar
  64. 64.
    Smith PG, Doll R. Mortality among patients with ankylosing spondylitis after a single treatment course with X-rays. Br Med J 1982; 284: 449–460.CrossRefGoogle Scholar
  65. 65.
    Klastersky J, Leleux A. Secondary neoplasms following cancer treatment with a special emphasis on lung tumors. Neoplasma 1991; 38 (3): 253–256.PubMedGoogle Scholar
  66. 66.
    Travis LB, Curtis RE, Boice JD, Hankey BF, Fraumeni JF. Second cancers following non-Hodgkin’s lymphoma. Cancer (Philadelphia) 1991; 67: 2002–2009.CrossRefGoogle Scholar
  67. 67.
    Van Leeuwen FE, Somers R, Tall BG, et al. Increased risk of lung cancer, non-Hodgkin’s lymphoma, and leukemia following Hodgkin’s disease. J Clin Oncol 1989; 7 (8): 1046–1058.PubMedGoogle Scholar
  68. 68.
    Lerman Y, Learman Y, Schacter P, Herceg E, Lieberman Y, Yellin A. Radiation-associated malignant pleural mesothelioma. Thorax 1991; 46: 463–464.PubMedCrossRefGoogle Scholar
  69. 69.
    Okazaki A, Matsuura M, Noda M, et al. Esophageal cancer developing 13 years after radiotherapy of lung cancer. Gann No Rinsho 1988; 34 (6): 787–793.Google Scholar
  70. 70.
    Louis S, Cross CE, Amott TR, Cardiff R. Postirradiation malignant fibrous histiocytoma of the trachea. Am Rev Respir Dis 1987; 135 (3): 761–762.Google Scholar
  71. 71.
    Shah IA, Kurtz SM, Simonsen RL. Radiation induced malignant fibrous hitiocytoma of the pulmonary artery. Arch Pathol Lab Med 1991; 115 (9): 921–925.PubMedGoogle Scholar
  72. 72.
    Einhorn L, Krause M, Hornback N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell cancer. Cancer (Philadelphia) 1976; 37: 2414 2416.Google Scholar
  73. 73.
    Soble AR, Perry H. Fatal radiation pneumonia following subclinical busulfun injury. AJR 1977; 128: 15–18.PubMedCrossRefGoogle Scholar
  74. 74.
    Buzdar AU, Legha SS, Luna MA, Tashima CK, Hortobagyi GN, Glumenschein GR. Pulmonary toxicity of mitomycin. Cancer (Philadelphia) 1980; 45: 236–244.CrossRefGoogle Scholar
  75. 75.
    Orwoll ES, Kiessling P, Patterson R, et al. Interstitial pneumonia from mitomycin. Ann Intern Med 1978; 89: 352–355.PubMedCrossRefGoogle Scholar
  76. 76.
    Rosenow EC, III. Drug-induced bronchopulmonary pleural disease. J Allergy Clin Immunol 1987; 80: 780787.Google Scholar
  77. 77.
    DeSwarte RD. Drug allergy: An overview. Clin Rev Allergy 1986; 4: 143–169.Google Scholar
  78. 78.
    Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. Semin Oncol 1982; 9: 34–51.PubMedGoogle Scholar
  79. 79.
    Israel-Biet D, Labrune S, Huchon GJ. Drug-induced lung disease: 1990 review. Eur Respir J 1991; 4: 465–478.PubMedGoogle Scholar
  80. 80.
    Demeter SL, Ahmad M, Tomashefski JF. Drug-induced pulmonary disease: Part 2. Categories of drugs. Clevel Clin Q 1979; 46 (3): 101–112.Google Scholar
  81. 81.
    Demeter SL, Ahmad M, Tomashefski JF. Drug-induced pulmonary disease: Part 3. Agents used to treat neoplasms or alter the immune system including a brief review of radiation therapy. Clevel Clin Q 1979; 46 (3): 113–124.Google Scholar
  82. 82.
    Cooper JAD, Jr., White DA, Matthay RA. Drug-induced pulmonary disease: Part 2. Noncytotoxic drugs. Am Rev Respir Dis 1986; 133: 488–505.PubMedGoogle Scholar
  83. 83.
    Zitnik RJ, Cooper JAD, Jr. Pulmonary disease due to antirheumatic agents. Clin Chest Med 1990; 11: 139150.Google Scholar
  84. 84.
    Myers JL. Pathology of drug-induced lung disease. In: Katzenstein ALA, Askin FB, eds. Surgical pathology of non-neoplastic lung disease. 2d Ed. Philadelphia: WB Saunders, 1990; 13: 97–127.Google Scholar
  85. 85.
    Smith GJ W. The histopathology of pulmonary reactions to drugs. Clin Chest Med 1990; 11: 95–117.PubMedGoogle Scholar
  86. 86.
    Bedrossian CWM. Pathology of drug-induced lung diseases. Semin Respir Med 1982; 4 (2): 98–105.CrossRefGoogle Scholar
  87. 87.
    Demeter SL, Ahmad M, Tomashefski JF. Drug-induced pulmonary disease: Part 1. Patterns of response. Clevel Clin Q 1979; 46 (3): 89–99.Google Scholar
  88. 88.
    Meeker DP, Wiedemann HP. Drug-induced bronchospasm. Clin Chest Med 1990; 11: 163–175.PubMedGoogle Scholar
  89. 89.
    Samter M, Beers RF, Jr. Concerning the nature of intolerance to aspirin. J Allergy 1967; 40: 281–293.PubMedCrossRefGoogle Scholar
  90. 90.
    Zeitz HJ. Bronchial asthma, nasal polyps, and aspirin sensitivity: Samter’s syndrome. Clin Chest Med 1988; 9: 567–576.Google Scholar
  91. 91.
    Slepian IK, Mathews KP, McLean JA. Aspirin-sensitive asthma. Chest 1985; 87: 386–391.PubMedCrossRefGoogle Scholar
  92. 92.
    Spector SL, Wangarrd CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 1979; 64: 500–506.PubMedCrossRefGoogle Scholar
  93. 93.
    Szceklik A, Nizankowska E, Czerniawska-Mysik G, Sek S. Hydrocortisone and airflow impairment in aspirin-induced asthma. J Allergy Clin Immunol 1985; 76: 530536.Google Scholar
  94. 94.
    Decalmer PBS, Chatterjee SS, Cruickshank JM, et al. Beta-blockers and asthma. Br HeartJ 1978; 40: 184–189.CrossRefGoogle Scholar
  95. 95.
    Gulekas D, Georgopoulos D, Papakosta D, et al. Influence of pindolol on asthmatic and effect of bronchodilators. Respiration 1986; 50: 158–166.CrossRefGoogle Scholar
  96. 96.
    Mattson K, Poppius II. Controlled study of the bronchoconstriction effect of pindolol administered intravenously or orally to patients with unstable asthma. Eur J Clin Pharmacol 1978; 14: 87–92.PubMedCrossRefGoogle Scholar
  97. 97.
    Grieco MH, Pierson RN, Jr. Mechanisms of bronchoconstriction due to beta-adrenergic blockage. J Allergy Clin Immunol 1971; 48: 143–152.PubMedCrossRefGoogle Scholar
  98. 98.
    Frishman W, Jacob H, Eisenberg E, Ribner H. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 8. Self-poisoning with beta-adrenoceptor blocking agents: Recognition and management. Am Heart J 1979; 98: 798–811.PubMedCrossRefGoogle Scholar
  99. 99.
    Beemer GH, Dennis WL, Platt PR, et al. Adverse reactions to atracurium and alcuronium. Br J Anaesth 1988; 61: 680–684.PubMedCrossRefGoogle Scholar
  100. 100.
    Bertrand P, Rouleau P, Alison D, Chastin I. Use of peak expiratory flow rate to identify patients with increased risk of contrast medium reaction. Results of preliminary study. Invest Radiol 1988; 23: 5203–5205.Google Scholar
  101. 101.
    Dawson P, Pitfield J, Britton J. Contrast media and bronchospasm: A study with iopamidol. Clin Radiol 1983; 34: 227–230.PubMedCrossRefGoogle Scholar
  102. 102.
    Littner MR, Ulreich S, Putman CE, et al. Bronchospasm during excretory urography. Lack of specificity for the methylglucamine cation. AJR 1981; 137: 477–481.PubMedCrossRefGoogle Scholar
  103. 103.
    Yarbrough J, Mansfield LE, Ting S. Metered dose inhaler-induced bronchospasm in asthmatic patients. Ann Allergy 1985; 55: 25–27.PubMedGoogle Scholar
  104. 104.
    Koepke JW, Seiner JC, Dunhill AL. Presence of sulfur dioxide in commonly used bronchodilator solutions. J Allergy Clin Immunol 1983; 72: 504–508.PubMedCrossRefGoogle Scholar
  105. 105.
    Koepke JW, Christopher KL, Chai H, Selner JC. Dose- 126. dependent bronchospasm from sulfites in isoetharine. JAMA 1984; 251: 2982–2983.PubMedCrossRefGoogle Scholar
  106. 106.
    Trautlein J, Allegra J, Field J, Gillin M. Paradoxic bronchospasm after inhalation of isoproterenol. Chest 127. 1976; 70: 711–714.CrossRefGoogle Scholar
  107. 107.
    Cocchetto DM, Sykes RS, Spector S. Paradoxical bronchospasm after use of inhalation aerosols: A review of 128. the literature. J Asthma 1991; 28: 49–53.PubMedCrossRefGoogle Scholar
  108. 108.
    Montgomery AB, Debs RJ, Luce JM, et al. Aerosolised pentamide as sole therapy for Pneumocystis carinii pneu- 129. monia in patients with acquired immunodeficiency syndrome. Lancet 1987;ii:480–483.Google Scholar
  109. 109.
    Alston TA. Inhibition of cholinesterases by pentamide 130. [letter]. Lancet 1988;ii:1423.Google Scholar
  110. 110.
    Paton WD. Aerosolised pentamidine [letter]. Lancet 1987;ii:1146.Google Scholar
  111. 111.
    Ligresti DJ. Anaphylaxis. Clin Dermatol 1986; 4: 40–49.PubMedCrossRefGoogle Scholar
  112. 112.
    James LP, Jr., Austin KF. Fatal systemic anaphylaxis in man. N Engl J Med 1964; 270: 597–603.PubMedCrossRefGoogle Scholar
  113. 113.
    Shkutin AE, Naresheva KA, Donchenko VS. Morphology and pathogenesis of changes in the lungs during 132. drug-induced anaphylactic shock in humans. Arkh Patol 1989; 51: 48–54.PubMedGoogle Scholar
  114. 114.
    Rosenow EC. Drug-induced pulmonary disease. Clin Notes Respir Dis 1977; 16 (1): 3–11.PubMedGoogle Scholar
  115. 115.
    Ginsburg WW. Drug-induced systemic lupus erythematosus. Semin Respir Med 1980; 2: 51–58.CrossRefGoogle Scholar
  116. 116.
    Solinger AM. Drug-related lupus. Clinical and etiologic considerations. Rheum Dis Clin North Am 1988; 14: 187–202.PubMedGoogle Scholar
  117. 117.
    Hess EV. Drug-related lupus: The same or different? In: Lahita RG, ed. Systemic lupus erythematosus. New York: Wiley, 1987: 869–880.Google Scholar
  118. 118.
    Jain KK. Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Safety 1991; 6 (5): 350–360.PubMedCrossRefGoogle Scholar
  119. 119.
    Haas C, Hugues FC, Le-Jeunne C. Drug-induced pleural pathology (excluding antineoplastic chemotherapy). Ann Med Interne 1989; 140 (7): 589–592.Google Scholar
  120. 120.
    Hindle W, Posner E, Sweetnam MT, Tan RSH. Pleural effusion and fibrosis during treatment with methysergide. Br Med J 1970; 1: 605–606.PubMedCrossRefGoogle Scholar
  121. 121.
    Reid J, Watson RD, Sproull DH. The mode of action of salicylate in acute rheumatic fever. Q J Med 1950; 19: 261–268.Google Scholar
  122. 122.
    Hormaechae E, Carlson RW, Rogove H, Uphold J, Henning RJ, Weil MH. Hypovolemia, pulmonary edema and protein changes in severe salicylate poisoning. Am J Med 1979; 66: 1046–1050.CrossRefGoogle Scholar
  123. 123.
    Osier W. Oedema of the lung complicating morphia poisoning. Montreal Gen Hosp Rep 1880; 1: 291–293.Google Scholar
  124. 124.
    Steinberg AD, Karliner JS. The clinical spectrum of heroin pulmonary edema. Arch Intern Med 1968; 122: 122–127.PubMedCrossRefGoogle Scholar
  125. 125.
    Smith WR, Wells ID, Glauser FL, Novey HS. Immunologic abnormalities in heroin lung. Chest 1975; 68: 651–653.CrossRefGoogle Scholar
  126. 126.
    Schmidt RA, Glenny RW, Godwin JD, Hampson NB, Cantino ME, Reichenbach DD. Panlobular emphysema in young intravenous Ritalin abusers. Am Rev Respir Dis 1991; 143: 649–656.PubMedCrossRefGoogle Scholar
  127. 127.
    Tomashefski JF, Hirsch CS. The pulmonary vascular lesions of intravenous drug abuse. Hum Pathol 1980; 11: 133–145.PubMedCrossRefGoogle Scholar
  128. 128.
    Flacke JW, Flacke WE, Williams GD. Acute pulmonary edema following naloxone reversal of high-dose morphine anesthesia. Anesthesiology 1977; 47: 376–378PubMedCrossRefGoogle Scholar
  129. 129.
    Glauser FL, Smith WR, Caldwell A, et al. Ethchlorvynol (Placidyl)-induced pulmonary edema. Ann Intern Med 1976; 84: 46–48.PubMedCrossRefGoogle Scholar
  130. 130.
    Margolin KA, Rayner AA, Hawkins MJ, et al. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 1989; 7: 486–498.PubMedGoogle Scholar
  131. 131.
    Saxon RR, Klein JS, Bar MH, et al. Pathogenesis of pulmonary edema during interleukin-2 therapy: Correlation of chest radiographic and clinical findings in 54 patients. AJR 1991; 156 (2): 281–286.PubMedCrossRefGoogle Scholar
  132. 132.
    Thompson JA, Shulman KL, Benyunes MC, et al. Prolonged continuous intravenous infusion interkeukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992; 10: 960–968.PubMedGoogle Scholar
  133. 133.
    Cantor JO. Bleomycin-induced pulmonary fibrosis: In: Cantor JO, ed. CRC handbook of animal models of pulmonary disease. Vol. I. Boca Raton: CRC Press, 1989: 117–130.Google Scholar
  134. 134.
    Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11: 1–20.PubMedGoogle Scholar
  135. 135.
    Santrach PJ, Askin FB, Wells RJ, Azizkhan RG, Merten DF. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma. Cancer (Philadelphia) 1989; 64: 806–811.CrossRefGoogle Scholar
  136. 136.
    Cohen MB, Austin JHM, Smith-Vaniz A, Lutzky J, Grimes MM. Nodular bleomycin toxicity. Am J Clin Pathol 1989; 92: 101–104.PubMedGoogle Scholar
  137. 137.
    White DA, Schwartzberg LS, Kris MG, Bosl GJ. Acute chest pain syndrome during bleomycin infusions. Cancer (Philadelphia) 1987; 59: 1582–1585.CrossRefGoogle Scholar
  138. 138.
    Oliner H, Schwartz R, Rubio F, Dameshek W. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med 1961; 31: 134–139.PubMedCrossRefGoogle Scholar
  139. 139.
    Twohig KJ, Matthay RA. Pulmonary effects of cytotoxic agents other than bleomycin. Clin Chest Med 1990; 11: 31–54.PubMedGoogle Scholar
  140. 140.
    Kuplic JB, Higley CS, Niewoehner DE. Pulmonary ossification associated with long-term busulfan therapy in chronic myeloid leukemia. Am Rev Respir Dis 1972; 106: 759–762.PubMedGoogle Scholar
  141. 141.
    Aymard JP, Gyger M, Lavallee R, et al. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia. A peculiar pathologic aspect of busulfan lung? Cancer (Philadelphia) 1984; 53: 954–956.CrossRefGoogle Scholar
  142. 142.
    Gould VE, Miller J. Sclerosing alveolitis induced by cyclophosphamide. Am J Pathol 1975; 81: 513–520.PubMedGoogle Scholar
  143. 143.
    Aronin PA, Mahaley MS, Rudnick SA, et al. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas. An assessment of risk factor. N Engl J Med 1980; 303: 183–191.PubMedCrossRefGoogle Scholar
  144. 144.
    Smith AC. The pulmonary toxicity of nitrosoureas. 165. Pharmacol Ther 1989; 44: 443–460.CrossRefGoogle Scholar
  145. 145.
    O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattamaneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990; 323: 378–382.PubMedCrossRefGoogle Scholar
  146. 146.
    Hasleton PS, O’Driscoll BR, Lynch P, et al. Late BCNU lung: A light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. J Pathol 1991; 164: 31–36.PubMedCrossRefGoogle Scholar
  147. 147.
    Bedrossian CWM, Miller WC, Luna MA. Methotrexateinduced diffuse intersitial pulmonary fibrosis. South Med J 1979; 72: 313–318.PubMedCrossRefGoogle Scholar
  148. 148.
    Sostman HD, Matthay RA, Putman CE, Walker-Smith GJ. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976; 55: 371–388.CrossRefGoogle Scholar
  149. 149.
    Kaplan RL, Waite DH. Progressive interstitial lung disease from prolonged methotrexate therapy. Arch Dermatol 1978; 114: 1800–1802.PubMedCrossRefGoogle Scholar
  150. 150.
    Phillips TJ, Jones DH, Baker H. Pulmonary complications following methotrexate therapy. J Am Acad Dermatol 1987; 16 (2 Pt. 1): 373–375.PubMedCrossRefGoogle Scholar
  151. 151.
    Myers JL, Kennedy JI, Plumb VJ. Amiodarone lung: Pathologic findings in clinically toxic patients. Hum Pathol 1987; 18: 349–354.PubMedCrossRefGoogle Scholar
  152. 152.
    Martin WJ, II. Mechanisms of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11: 131–138.PubMedGoogle Scholar
  153. 153.
    Holmberg L, Boman G. Pulmonary reactions to nitrofurantoin. Eur J Respir Dis 1981; 62: 180–189.PubMedGoogle Scholar
  154. 154.
    Sovijärvi ARA, Lemola M, Stenius B, Idänpään-Heikkilä J. Nitrofurantoid-induced acute, subacute and chronic pulmonary reactions. Scand J Respir Dis 1977; 58: 4150.Google Scholar
  155. 155.
    Wykoff RF. Eosinophilia. South Med J 1986;79(5):608–612.Google Scholar
  156. 156.
    Kawanami O, Basset F, Barrios R, Lacronique JG, Ferrans VJ, Crystal RG. Hypersensitivity pneumonitis in man: Light and electron-microscopic studies of 18 lung biopsies. Am J Pathol 1983; 110: 275–289.PubMedGoogle Scholar
  157. 157.
    Coleman A, Colby TV. Histologic diagnosis of extrinsic allergic alveolitis. Am J Surg Pathol 1988; 2: 514–518.CrossRefGoogle Scholar
  158. 158.
    Cooper JA, Jr., Matthay RA. Drug-induced pulmonary disease. Dis Mon 1987; 33 (2): 61–120.PubMedCrossRefGoogle Scholar
  159. 159.
    Goodwin SD, Glenny RW. Nonsteroidal antiinflammatory drug-associated pulmonary infiltratres with eosinophilia: Review of the literature and FDA adverse drug reaction reports. Arch Intern Med 1992; 152: 1521–1524.PubMedCrossRefGoogle Scholar
  160. 160.
    Geddes DM. Pulmonary eosinophilia. J R Coll Physicians Lond 1986; 20 (2): 139–145.PubMedGoogle Scholar
  161. 161.
    Kay AB. Biological properties of eosinophils. Clin Exp Allergy 1991; 21 (Suppl. 3): 23–29.PubMedCrossRefGoogle Scholar
  162. 162.
    Weller PF. The immunobiology of eosinophils. N Engl J Med 1991; 324: 1110–1118.PubMedCrossRefGoogle Scholar
  163. 163.
    Kennedy JI, Jr. Clinical aspects of amiodarone pulmonary toxicity. Clin Chest Med 1990; 11: 119–129.PubMedGoogle Scholar
  164. 164.
    Wilson BD, Clarkson CE, Lippman ML. Amiodarone induced pulmonary inflammation: Correlation with drug dose and lung levels of drug, metabolite and phospholipid. Am Rev Respir Dis 1981; 143: 1110–1114.CrossRefGoogle Scholar
  165. 165.
    Yousem SA, Berry GJ, Chamberlain D, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Lung rejection study group. J Heart Lung Transplant 1990; 9: 593–601.Google Scholar
  166. 166.
    Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-vhost disease and low serum IgG. Blood 1988; 72: 62 1627.Google Scholar
  167. 167.
    Epler GR. Bronchiolis obliterans and airways obstruction associated with graft-versus-host disease. Clin Chest Med 1988; 9: 551–556.PubMedGoogle Scholar
  168. 168.
    Paz HL, Crilley P, Patchefsky A, Schiffman RL, Brodsky I. Bronchiolitis obliterans after autologous bone marrow transplantation. Chest 1992; 101: 775–778.Google Scholar
  169. 169.
    Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152–158.PubMedCrossRefGoogle Scholar
  170. 170.
    Aymard J-P, Gyger M, Lavallee R, Legresley L-P, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia: A peculiar manifestation of busulfan lung? Cancer (Philadelphia) 1984; 53: 954–956.CrossRefGoogle Scholar
  171. 171.
    Myers JL, Katzenstein AA. Wegener’s granulomatosis presenting with massive pulmonary hemorrhage and capillaritis. Am J Surg Pathol 1987; 11: 895–898.PubMedCrossRefGoogle Scholar
  172. 172.
    Colby TV. Diffuse pulmonary hemorrhage in Wegen-er’s granulomatosis. Semin Respir Med 1989; 10: 136140.Google Scholar
  173. 173.
    Johnson MP, Goodwin SD, Shands JW, Jr. Trimethoprim-sulfamethoxazole anaphylactoid reactions in patients with AIDS: Case reports and literature review. Pharmacotherapy 1990; 10: 413–416.Google Scholar
  174. 174.
    Ahmad S. Lovastatin-induced lupus erythmatosus. Arch Intern Med 1991; 151 (8): 1667–1668.PubMedCrossRefGoogle Scholar
  175. 175.
    Miller DH, Haas LF. Pneumonitis, pleural effusion and pericarditis following treatment with dantrolene. J Neurol Neurosurg Psychiatry 1984; 47 (5): 553–554.PubMedCrossRefGoogle Scholar
  176. 176.
    Hind CRK. Pulmonary complications of intravenous drug misuse-2: Infective and HIV related complications. Thorax 1990; 45: 957–961.Google Scholar
  177. 177.
    Heffner JE, Harley RA, Schabel SI. Pulmonary reactions from illicit substance abuse. Clinics Chest Med 1990; 11 (1): 151–162.Google Scholar
  178. 178.
    Libby LS, King TE, LaForce FM, Schwartz MI. Pulmonary cavitation following pulmonary infarction. Medicine (Baltimore) 1985; 64 (5): 342–348.Google Scholar
  179. 179.
    Navarro C, Dickinson PCT, Kondlapoodi P, Hagstrom JWC. Mycotic aneurysms of the pulmonary arteries in intravenous drug addicts: Report of three cases and review of the literature. Am J Med 1984; 76: 1124–1131.PubMedCrossRefGoogle Scholar
  180. 180.
    Hind CRK. Pulmonary complications of intravenous drug misuse-1: Epidemiology and non-infective complications. Thorax 1990; 45: 891–898.Google Scholar
  181. 181.
    Hopkins GB. Pulmonary angiothrombotic granulomatosis in drug offenders. JAMA 1972; 221 (8): 909–911.PubMedCrossRefGoogle Scholar
  182. 182.
    Paré JAP, Fraser RG, Hogg JC, Howlett JG, Murphy SB. Pulmonary `mainline’ granulomatosis: Talcosis of intravenous methadone abuse. Medicine (Baltimore) 1979; 58 (3): 229–239.Google Scholar
  183. 183.
    Crouch E, Churg A. Progressive massive fibrosis of the lung secondary to intravenous injection of talc. A pathologic and mineralogic analysis. Am J Clin Pathol 1983; 80: 520–526.PubMedGoogle Scholar
  184. 184.
    Paré JP, Cote G, Fraser RS. Long-term follow-up of drug abusers with intravenous talcosis. Am Rev Respir Dis 1989; 139: 233–241.PubMedCrossRefGoogle Scholar
  185. 185.
    Groth DH, Mackay GR, Crable JV, Cochran TH. Intravenous injection of talc in a narcotics addict. Arch Pathol 1972; 94: 171–178.PubMedGoogle Scholar
  186. 186.
    Vevaina JR, Civantos F, Viamonte M, Jr., Avery WG. Emphysema associated with talcum granulomatosis in a drug addict. South Med J 1974; 67: 113–116.PubMedCrossRefGoogle Scholar
  187. 187.
    Sherman CB, Hudson LD, Pierson DJ. Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. Chest 1987; 92: 1085–1087.PubMedCrossRefGoogle Scholar
  188. 188.
    Tashkin DP. Pumonary complications of smoked sub stance abuse. West J Med 1990; 152: 525–530.PubMedGoogle Scholar
  189. 189.
    Brody SL, Slovis CM, Wrenn KD. Cocaine-related medical problems: Consecutive series of 233 patients. Am J Med 1990; 88: 325–331.PubMedCrossRefGoogle Scholar
  190. 190.
    Oubeid M, Bickel JT, Ingram EA, Scott GC. Pulmonary talc granulomatosis in a cocaine sniffer. Chest 1990; 98: 237–239.PubMedCrossRefGoogle Scholar
  191. 191.
    Ettinger NA, Albin RJ. A review of the respiratory effects of smoking cocaine. Am J Med 1989; 87: 664–668.PubMedCrossRefGoogle Scholar
  192. 192.
    Tashkin DP, Khalsa M-E, Gorelick D, et al. Pulmonary status of habitual cocaine smokers. Am Rev Respir Dis 1992; 145: 92–100.PubMedCrossRefGoogle Scholar
  193. 193.
    Forrester JM, Steele AW, Waldron JA, Parsons PE. Crack lung: An acute pulmonary syndrome with a spectrum of clinical and histopathologic findings. Am Rev Respir Dis 1990; 142: 462–467.PubMedCrossRefGoogle Scholar
  194. 194.
    Susskind H, Weber DA, Volkow ND, Hitzemann R. Increased lung permeability following long-term use of free-base cocaine (crack). Chest 1991; 100: 903–909.PubMedCrossRefGoogle Scholar
  195. 195.
    Murray RJ, Smialek JE, Golle M, Albin RJ. Pulmonary artery medial hypertrophy in cocaine users without foreign particle microembolization. Chest 1989; 96: 1050–1053.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Rodney A. Schmidt

There are no affiliations available

Personalised recommendations